Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
12 2020
Historique:
received: 17 08 2020
accepted: 21 09 2020
pubmed: 5 10 2020
medline: 20 4 2021
entrez: 4 10 2020
Statut: ppublish

Résumé

BRCA mutation carriers face a high lifetime risk of developing ovarian cancer. The strong inverse association between breastfeeding and the risk of ovarian cancer is established in the general population but is less well studied among women with a germline BRCA1 or BRCA2 mutation. Thus, we conducted a matched case-control analysis to evaluate the association between breastfeeding history and the risk of developing ovarian cancer. After matching for year of birth, country of residence, BRCA gene and personal history of breast cancer, a total of 1650 cases and 2702 controls were included in the analysis. Conditional logistic regression was used to estimate the odds ratio (OR) and 95% confidence intervals (CI) associated with various breastfeeding exposures. A history of ever-breastfeeding was associated with a 23% reduction in risk (OR = 0.77; 95%CI 0.66-0.90; P = 0.001). The protective effect increased with breastfeeding from one month to seven months after which the association was relatively stable. Compared to women who never breastfed, breastfeeding for seven or more months was associated with a 32% reduction in risk (OR = 0.68; 95%CI 0.57-0.81; P < 0.0001) and did not vary by BRCA gene or age at diagnosis. The combination of breastfeeding and oral contraceptive use was strongly protective (0.47; 95%CI 0.37-0.58; P < 0.0001). These findings support a protective effect of breastfeeding for at least seven months among women with a BRCA1 or BRCA2 mutation, that is independent of oral contraceptive use.

Identifiants

pubmed: 33010967
pii: S0090-8258(20)33947-0
doi: 10.1016/j.ygyno.2020.09.037
pii:
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0
Contraceptives, Oral 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

820-826

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All the authors declare that they have no conflict of interest.

Auteurs

Joanne Kotsopoulos (J)

Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Jacek Gronwald (J)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.

Jeanna M McCuaig (JM)

Division of Gynecologic Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada.

Beth Y Karlan (BY)

Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.

Andrea Eisen (A)

Toronto-Sunnybrook Regional Cancer Center, Toronto, ON, Canada.

Nadine Tung (N)

Beth Israel Deaconess Medical Center, Boston, MA, USA.

Louise Bordeleau (L)

Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada.

Leigha Senter (L)

Division of Human Genetics, the Ohio State University Medical Center, Comprehensive Cancer Center, Columbus, OH, USA.

Charis Eng (C)

Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Center for Personalised Genetic Healthcare, Cleveland Clinic Community Care and Population Health, Cleveland, OH, USA.

Fergus Couch (F)

Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

Robert Fruscio (R)

Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy.

Jeffrey N Weitzel (JN)

Division of Clinical Cancer Genomics, Department of Population Sciences, City of Hope, Duarte, CA, USA.

Olufunmilayo Olopade (O)

Department of Medicine and Human Genetics, University of Chicago, Chicago, IL, USA.

Christian F Singer (CF)

Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Tuya Pal (T)

Department of Medicine, Vanderbilt University, Nashville, TN, USA.

William D Foulkes (WD)

Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montréal, QC, Canada.

Susan L Neuhausen (SL)

Division of Biomarkers of Early Detection and Prevention, Department of Population Sciences, City of Hope, Duarte, CA, USA.

Ping Sun (P)

Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.

Jan Lubinski (J)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.

Steven A Narod (SA)

Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. Electronic address: steven.narod@wchospital.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH